<! DOCTYPE = html>
<html>
<title>CS657 - Prescription</title>
<style>
div.container {
		width: 100%;
		border: 1px solid gray;
}

header{
		padding: 0.5em;
		#color: black;
		background-color: orange;
		clear: left;
		text-align: center;
}
.footer{
		padding : 1em;
		background-color: orange;
		text-align: center;
		<!--- position: fixed;>
		bottom : 0;
		width : 100%;
}

nav {
		float: left;
		max-width: 160px;
		margin: 0;
		padding: 1em;
}

nav ul {
		list-style-type: none;
		padding: 0;
}
	 
nav ul a {
		text-decoration: none;
}

article {
		margin-left: 170px;
		border-left: 1px solid gray;
		padding: 1em;
		overflow: hidden;
}
table {
		font-family: arial, sans-serif;
		border-collapse: collapse;
		width: 80%;
}

td, th {
		border: 4px solid #000000;
		text-align: middle;
		padding: 8px;
}

tr:nth-child(even) {
		background-color: #eeeeee;
}	

div.box {
		background-color: white;
		width: 300px;
		border: 2px solid green;
		padding: 10px;
		margin: 25px;
}
</style>
<body>
<div class="container">
	<header><h1>
		IIT Kanpur Medical Labs</h1>
	</header>
	<hr>	<h2> Precription for the query: </h2>
	<div class="box">
	weight loss, overweight, low body mass index
	</div>
	<hr>	<h2>
		Identified Disease: </h2>
	<div class="box">
	Metabolic Syndrome X
	</div>
	<hr>	<h2>More Symptoms: </h2>
	<div class="box">
	Akathisia, Headache, Hearing Loss, Diarrhea, Mobility Limitation
	</div>
		<hr><h2>
Medication:</h2>
<table>
	<tr>
		<th>Serial No</th>
		<th>Drug Name</th>
		<th>Group</th>
		<th>Indication</th>
	</tr>	<tr>
		<td>1.</td>
		<td>Warfarin</td>
		<td>Approved</td>
		<td>For the treatment of retinal vascular occlusion, pulmonary embolism, cardiomyopathy, atrial fibrillation and flutter, cerebral embolism, transient cerebral ischaemia, arterial embolism and thrombosis.</td>
	</tr>	<tr>
		<td>2.</td>
		<td>Stiripentol</td>
		<td>Approved</td>
		<td>Indicated for use in conjunction with clobazam and valproate as adjunctive therapy of refractory generalized tonic-clonic seizures in patients with severe myoclonic epilepsy in infancy (SMEI, Dravet’s syndrome) whose seizures are not adequately controlled with clobazam and valproate.</td>
	</tr>	<tr>
		<td>3.</td>
		<td>Grapefruit</td>
		<td>Approved</td>
		<td>Not Available</td>
	</tr>	<tr>
		<td>4.</td>
		<td>Albiglutide</td>
		<td>Approved</td>
		<td>Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.</td>
	</tr>	<tr>
		<td>5.</td>
		<td>Enoxaparin</td>
		<td>Approved</td>
		<td>For the prophylaxis of deep vein thrombosis, which may lead to pulmonary embolism, and also for the prophylaxis of ischemic complications of unstable angina and non-Q-wave myocardial infarction, when concurrently administered with aspirin.</td>
	</tr>	<tr>
		<td>6.</td>
		<td>Idursulfase</td>
		<td>Approved</td>
		<td>For the treatment of Hunter syndrome in adults and children ages 5 and older.</td>
	</tr>	<tr>
		<td>7.</td>
		<td>Obeticholic acid</td>
		<td>Approved</td>
		<td>Investigated for use/treatment in liver disease.Obeticholic acid was approved as an orphan drug based on its reduction in the level of the biomarker alkaline phosphatase as a surrogate endpoint for clinical benefit. It is indicated for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as monotherapy in adults unable to tolerate UDCA. Additional studies are being required to prove its clinical benefit.</td>
	</tr>	<tr>
		<td>8.</td>
		<td>Blinatumomab</td>
		<td>Approved, Investigational</td>
		<td>Indicated for the treatment of Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).</td>
	</tr>	<tr>
		<td>9.</td>
		<td>Decitabine</td>
		<td>Approved, Investigational</td>
		<td>For treatment of patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS of all French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups (scores ≥0.5).</td>
	</tr>	<tr>
		<td>10.</td>
		<td>Immune Globulin Human</td>
		<td>Approved, Investigational</td>
		<td>IVIg is used in the treatment of immunodeficiencies, as well as autoimmune and inflammatory disorders. These indications includes idiopathic thrombocytopenic purpura, Kawasaki disease, hypogammaglobulinemia, B cell chronic lymphocytic leukemia, bone marrow transplant complications, Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy (CIDP), multiple sclerosis, rheumatoid arthritis, myesthenia gravis, Wiskott–Aldrich syndrome and inflammatory skin diseases.</td>
	</tr>	<tr>
		<td>11.</td>
		<td>Coagulation factor X human</td>
		<td>Approved, Investigational</td>
		<td>Indicated in adults and children (aged 12 years and above) with hereditary Factor X deficiency for on-demand treatment and control of bleeding episodes, or for perioperative management of bleeding in patients with mild hereditary Factor X deficiency [FDA Label]. </td>
	</tr>	<tr>
		<td>12.</td>
		<td>Elosulfase alfa</td>
		<td>Approved, Investigational</td>
		<td>Vimizim is a hydrolytic lysosomal glycosaminoglycan (GAG)-specific enzyme indicated for patients with Mucopolysaccharidosis type IVA (MPS IVA; Morquio A syndrome). </td>
	</tr>	<tr>
		<td>13.</td>
		<td>Vestronidase alfa</td>
		<td>Approved, Investigational</td>
		<td>Indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII (MPS VII, Sly syndrome).</td>
	</tr>	<tr>
		<td>14.</td>
		<td>Calcium carbimide</td>
		<td>Approved, Withdrawn</td>
		<td>Calcium carbimide has not been approved by the FDA but the intended indication is for the treatment of alcoholism.[6] This medication was marketed in Canada, United Kingdom and Europe under the trade name of Temposil for the sole use of alcoholism treatment.[9]</td>
	</tr>	<tr>
		<td>15.</td>
		<td>Tegaserod</td>
		<td>Approved, Investigational, Withdrawn</td>
		<td>Provides relief from the symptoms of irritable bowel syndrome including chronic idiopathic constipation.</td>
	</tr>	<tr>
		<td>16.</td>
		<td>Dexloxiglumide</td>
		<td>Investigational</td>
		<td>For the treatment of Irritable Bowel Syndrome (IBS) and Gastroesophageal Reflux Disease (GERD).</td>
	</tr>	<tr>
		<td>17.</td>
		<td>Prasterone sulfate</td>
		<td>Investigational</td>
		<td>Investigated for use/treatment in asthma and burns and burn infections.</td>
	</tr>	<tr>
		<td>18.</td>
		<td>Crocin</td>
		<td>Investigational</td>
		<td>Not Available</td>
	</tr>	<tr>
		<td>19.</td>
		<td>Aramchol</td>
		<td>Investigational</td>
		<td>Not Available</td>
	</tr>	<tr>
		<td>20.</td>
		<td>Varespladib methyl</td>
		<td>Investigational</td>
		<td>Investigated for use/treatment in atherosclerosis and coronary artery disease.</td>
	</tr>	<tr>
		<td>21.</td>
		<td>Eltanolone</td>
		<td>Investigational</td>
		<td>Not Available</td>
	</tr>	<tr>
		<td>22.</td>
		<td>Fenobam</td>
		<td>Investigational</td>
		<td>Not Available</td>
	</tr>	<tr>
		<td>23.</td>
		<td>Arbaclofen</td>
		<td>Investigational</td>
		<td>Investigated in clinical trials as a potential treatment for spasticity in multiple sclerosis, autism spectrum disorder, and social withdrawal in fragile X syndrome.</td>
	</tr>	<tr>
		<td>24.</td>
		<td>Basimglurant</td>
		<td>Investigational</td>
		<td>Not Available</td>
	</tr>	<tr>
		<td>25.</td>
		<td>LY-518674</td>
		<td>Investigational</td>
		<td>Not Available</td>
	</tr></table>
<div class="footer"> Copyright &copy : IIT Kanpur
</div>	
</div>
</body>
</html>